TRUPCR® AML Panel Kit

• CE-IVD • TRUPCR® AML Panel Kit allows comprehensive detection of most common diagnostic and prognostic markers for acute myelogenous leukaemia (AML) . • It detects most common variants of transcripts in the fusion gene and most common mutations in prognostics markers. • The AML PCR test offers sensitivity to detect up to 10 copies of fusion transcripts for AML1-ETO, CBFB- MYH11, BCR-ABL1, PML-RARA and up to 1% mutant allele in background of 98% wild type allele for c-KIT, NPM1, FLT3-ITD and FLT3-D835. • All the reagents for cDNA chemistry, PCR and Real-time PCR are included in the kit. • It is compatible with various Real-time & Conventional PCR instruments. • Easy-to-use, rapid, reliable, comprehensive and cost-effective tests.

The TRUPCR® AML Panel Kit is intended for the qualitative detection of diagnostic and prognostic markers of acute myelogenous leukaemia (AML) in peripheral blood samples on conventional and Real-time PCR technologies. Acute myeloid leukaemia (AML) is a group of haematological diseases, phenotypic and genetically heterogeneous, characterized by clonal expansion of myeloid precursors with diminished capacity for differentiation. AML represents 15 to 20% of acute leukaemia cases in children and 80% in adults. Myelogenous leukaemia is present when myeloid cell lineages such as granulocytes or monocytes are affected.